All In Biotech

Drug Trial Radar · NCT07021261

Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients

A Multicenter, Open-Label, Randomized, Phase III Study Comparing UTD2 Combined With Capecitabine to Capecitabine Monotherapy as Adjuvant Therapy for Triple-Negative Breast Cancer Patients Who Did Not Achieve Pathological Complete Response

Last checked: Nov 19, 2026Latest source record: Jun 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 440 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

440

Planned (sponsor's estimate)

Start

Jun 16, 2025

Primary completion

Jun 16, 2030

Study completion Jun 16, 2032

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the IDFS rate, overall survival (OS) rate, and safety profile of UTD2 combined with capecitabine versus capecitabine monotherapy as adjuvant therapy for triple-negative early breast cancer patients who did not achieve pathological complete response (pCR) after neoadjuvant therapy.

Conditions

  • Breast Cancer
  • TNBC

Interventions

  • Utidelone plus capecitabineDrug

    UTD2 50 mg/m²/day orally on Days 1-5, repeated every 21 days for 2 years; Capecitabine 1000 mg/m² twice daily on Days 1-14, repeated every 21 days for 8 cycles.

  • CapecitabineDrug

    Capecitabine 1000 mg/m² twice daily on Days 1-14, repeated every 21 days for 8 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 3-year invasive disease-free survival(IDFS)Time frame: 36 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.